An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
Kathy Miller, MD
Primary Investigator
Overview
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer.
Description
The purpose of this study is to evaluate the safety of Gedatolisib plus PTK7-ADC in patients with metastatic triple-negative or estrogen poor breast cancer as assessed by NCI CTC v4.0 criteria.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Metastatic Triple-negative Breast Cancer
Willingness to undergo tumor biopsy
Patients must have received at least 1 prior chemotherapy regimen for metastatic disease
Exclusion Criteria
Previous treatment with mTOR inhibitor
Untreated brain metastases